there is no report of the use of collateral-related donor for haplo transplant using PTCY as GvHD prophylaxis. Here we report such three cases who received a T-replete haploidentical allo-SCT with PTCY from their second-degree relative nephews.
CASE #1
In 2010, a 56-year-old male was diagnosed with ALK-CD30+ anaplastic T-cell lymphoma and received eight cycles of CHOD allowing achievement of morphological and metabolic partial response. The patient received an allo-SCT from a sibling-matched donor (brother) on November 2010 after a fludarabin-/busulfan-(FB2A2) based reduced intensity conditioning regimen. Graft failure was rapidly documented despite donor lymphocyte infusions. Relapse occurred in September 2014 and brentuximab vedotin was administered each 21 days for seven cycles allowing again a complete morphological and metabolic response. It was decided to perform a second allograft using a different donor. The patient was childless and no unrelated donor or cord blood units were available. It was thus chosen to ask the son of the matched brother, who was haploidentical, to be a donor. No antibodies directed against the donor's HLA specificities were documented in the patient. This nephew had a O-blood group and a negative CMV serology, whereas the recipient was O+ and CMV+. The second allograft was performed in this now 60-year-old patient on 2 April 2015 using the Baltimore-2 conditioning regimen with 2 days (days +3 and +4) of PTCY. Peripheral blood stem cells were used as the stem cell source instead of bone marrow (14.16 × 10 6 CD34+ cells per kg of recipient administered at day 0), and cyclosporine A and mycophenolate mofetyl were prescribed as GvHD prophylaxis. Neutrophil and platelet recovery (450 × 10 9 /L) was achieved as early as days +18 and +33, respectively, with full-donor whole-blood (WB) chimerism (99.8%) at day +30, persisting on days +60 and +100 (WB: 99.9%, CD3+ T cells: 99.9% at both time points). Grade 2 acute cutaneous GvHD occurred at day +21. The evolution was favorable after initiating corticosteroids at 2 mg/kg/day with tapering thereafter. Not surprisingly, CMV reactivation was documented at day +22, controlled by ganciclovir treatment. Immune reconstitution evaluated at days +30, +60 and +100 showed normal monocyte counts, whereas B lymphocytes were undetectable. Natural killer (NK) cells increased from 42 per mm 3 at day +30 to 453 per mm 3 at day +60 and 665 per mm 3 at day +100. Interestingly, after profound lymphopenia within the first 100 days post transplant, CD8+ T-large granular lymphocyte expansion was documented at day +110 and still persists. At 1 year, while the NK cell count was normal, B-cell lymphopenia was still present (44 per mm 3 ). At last follow-up, 22 months after the second transplant, the patient is alive in persistent morphological and metabolic remission with no active acute or chronic GvHD, or active infection.
CASE #2
This was a 59-year-old male who was documented with a doublehit (c-myc and Bcl-6 mutated) high-grade B-cell lymphoma on October 2014 with bone marrow infiltration. Before allo-SCT, the treatment consisted of one course of COP, then one course of R-COPADEM and one course of CYVE for two cycles. At the end of this, neurological symptoms (motor and sensitive deficit of both legs with urinary sphincter dysfunction) appeared but relapse, although suspected, was not proven. The patient received another four courses of R-CHOP and the decision to perform a tandem auto/allograft sequence, as consolidation was retained after establishing the improvement of neurological symptoms. The autograft was performed in May 2015 using a BEAM conditioning. Disease evaluation post autograft was in favor of partial response. A matched-unrelated donor has been identified for this patient having a twin brother who was finally recused for cell donation. Because of the severity of the disease it was chosen to ask for the son of the twin brother to be a donor. This nephew was a 24-year-old male with an AB-blood group and a negative CMV serology while the recipient was A+ and CMV-. No antibodies directed against the donor's HLA specificities were documented in the patient. The allograft was performed in this now 60-year-old patient on 28 August 2015 using the Baltimore-conditioning regimen with 2 days of PTCY. The peripheral stem cell dose administered at day 0 was 11.44 × 10 6 CD34+ cells per kg of recipient. Neutrophils and platelets recovery (450 × 10 9 /L) was achieved at days +14 and +33, respectively, with full-donor WB chimerism (99.8%) at day +20, persisting on days +80 and +100 (WB: 99.9%, CD3+ T cells: 99.9% at both time points). No acute or chronic GvHD occurred. Also, no CMV or EBV reactivations were documented. Disease evaluation showed morphological and metabolic remission as soon as day +100. Immune reconstitution evaluated at day +100 and at 6 months showed normal monocyte counts, whereas B lymphocytes increased from 9 to 127 per mm 3 , NK cells from 82 to 110 per mm 3 , CD4+ T cells from 252 to 402 per mm 3 and CD8+ T cells from 104 to 232 per mm 3 . At 17 months post transplant, the patient is alive in persistent morphological and metabolic remission, with no active acute or chronic GvHD, or active infection. Neurological sequelae with paraparesis and persistent lymphopenia (1180 per mm 3 ) are still present.
CASE #3
In 1993, a 38-year-old female was diagnosed with CML. /L) was achieved as early as days +19 and +26, respectively, with full-donor WB chimerism (99.8%) at day +36, persisting on day +60 and +100 (WB: 99.9%, CD3+ T cells: 99.9% at both time points). Molecular remission was documented as early as day +36. Grade 2 acute GvHD of the gut occurred at day +65. The evolution was favorable after initiating corticosteroids at 2 mg/kg/day with tapering thereafter. No CMV or EBV reactivations were observed. Immune reconstitution evaluated at days +30 and +100 showed normal monocyte counts and persistent lymphopenia. B lymphocytes, undetectable at day +30 were at 22 per mm 3 at day +100. NK cells increased from 23 to 254 per mm 3 , reaching normal counts. CD4+ T cells remained stable (36 and 32 per mm 3 ), whereas CD8+ T cells decreased from 250 to 9 per mm 3 . Molecular relapse was documented at 7 months. The patient received lymphocyte donor infusion twice at 1 × 10 5 CD3+ T cells per kg of recipient in November 2016 and 5 × 10 5 CD3 per kg of recipient in January 2017 with decrease of minimal residual disease and no GvHD.
In conclusion, T-replete haploidentical allo-SCT with high-dose PTCY using a second-degree relative donor is demonstrated here to be feasible allowing for full engraftment and moderate acute GvHD. As for the number of mismatched HLA antigens on the non-shared haplotype, 4 second-degree relative donor does not seem to play an unfavorable role after T-cell replete haploidentical allo-SCT using high-dose PTCY. However, investigations of locusspecific effects are still scarce in this setting and high-resolution HLA typing or HLA typing by next-generation sequencing methods is likely to change matching algorithms in the next future. 5 Also, our result demonstrates that the use of a second-degree relative as haplo donor should not be a limitation from the standpoint of matching, and as such expands the possibility to find a donor for a selected patient. However, some collateralrelated haplo donors may be less available or motivated than firstdegree haplo donors and could refuse to donate. The recent demonstration that use of unrelated haplo donor is feasible, 6 may help to resolve this problem.
Finally, our results showed that we might be on the way to get rid of the major HLA barrier. The latter could be of particular interest when considering solid transplantation. Indeed, combining solid organ transplantation and allo-SCT from the same haploidentical or full-HLA-mismatched donor could allow to lessen and even withdraw immunosuppression in this particular setting, because stable tolerance can be induced in this context, as it has been already reported for kidney transplant.
